ArticleNature cancer2025
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8
Abstract read
In one paragraph
Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Spatiotemporal dynamics of adoptively transferred stem-like CD8bioRxiv : the preprint server for biology · 2026Article
- Dynamic landscape of peripheral blood lymphocyte subsets in dengue patients: a multimodal single-cell and flow cytometry analysis.BMC infectious diseases · 2026Article
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Integrated single-cell and Mendelian randomization analyses: dissecting underlying causes of varied efficacy in immune neoadjuvant therapy for esophageal carcinoma.Discover oncology · 2025Article
- Cytotoxic T Cells: Kill, Memorize, and Mask to Maintain Immune Homeostasis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Liuling XiaoHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA. xiaoliuling@cqmu.edu.cn.ORCID http://orcid.org/0000-0002-3013-4523
Rui DuanHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Wendao LiuThe University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5124-9338
Chuanchao ZhangHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Xingzhe MaHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Miao XianHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0009-0007-6001-1077
Qiang WangHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6141-0068
Qi GuoHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Wei XiongHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8087-5047
Pan SuHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Lingqun YeHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Yabo LiHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Ling ZhongHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Jianfei QianHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
Yong LuHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0077-0040
Zhongming ZhaoThe University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3477-0914
Qing YiHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA. qyi@houstonmethodist.org.ORCID http://orcid.org/0000-0003-1529-3398
Funding
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustionR01CA239255 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2019 to 2023
$2.1MNovel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cellsR01CA282099 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Qing Yi · 2023 to 2026
$1.9MA novel T-cell subset able to kill relapsed cancersR01CA200539 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI YI, QING · 2016 to 2020
$1.8MTumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumorsR01CA285209 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Qing Yi · 2024 to 2026
$1.5MNCI NIH HHS R01 CA200539NCI NIH HHS R01 CA239255NCI NIH HHS R01 CA282099NCI NIH HHS R01 CA285209U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA200539U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA239255U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA282099U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA2855209
Abstract
Host effector CD4
Indexed as
Adoptive TransferAntigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunotherapy, AdoptiveNeoplasmsT-Lymphocytes, CytotoxicAnimalsCell Line, TumorDendritic CellsHumansInterleukin-24InterleukinsLymphocyte ActivationMiceMice, Inbred C57BLAntigens, NeoplasmInterleukin-24Interleukins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.